Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Catumaxomab

Phase 3Monoclonal antibody

NNeovii Biotech

Catumaxomab is one of 165 small molecule programs targeting Ascites. It is currently in Phase 3.

6

Indications

15

Total Trials

0

Active Trials

164

Competitors

Pipeline

Status by Indication[3][1]

Indication

AscitesActive, not recruiting

Gastric AdenocarcinomaActive, not recruiting

Ovarian CancerActive, not recruiting

Bladder CancerActive, not recruiting

Gastric CancerActive, not recruiting

Gastric CarcinomaActive, not recruiting

AscitesPhase 3

Active, not recruiting

Gastric AdenocarcinomaPhase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Bladder CancerPhase 1/Phase 2

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Gastric CarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Tecentriq

Cytoxan

BBaxter Healthcare Corporation

Vepesid

Jemperli

GGlaxo Dba Glaxosmithkline

IV Iron

Catumaxomab

NNeovii Biotech

Chiauranib

CChipscreen Biosciences, Ltd.

Salvage Chemotherapy

Fluzoparib; Apatinib

JJiangsu HengRui Medicine Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian Cancer4 trials

Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission

Completed·GGrupo Español de Investigación en Cáncer de Ovario·Phase 2·NCT01246440·39 enrolled

Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer

Completed·NNeovii Biotech·Phase 2·NCT00563836·41 enrolled

Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy

Completed·NNeovii Biotech·Phase 2·NCT00377429·47 enrolled

Show 1 more trial

Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer

Completed·JJSehouli·Phase 2·NCT01815528·2 enrolled

Ascites4 trials

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Completed·NNeovii Biotech·Phase 2·NCT00326885·32 enrolled

Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites

Completed·NNeovii Biotech·Phase 2·NCT01065246·8 enrolled

CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers

Completed·NNeovii Biotech·Phase 3·NCT00822809·230 enrolled

Show 1 more trial

Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group

Completed·NNeovii Biotech·Phase 2/3·NCT00836654·258 enrolled

NMIBC1 trial

Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

Unknown status·LLindis Biotech GmbH·Phase 1·NCT04819399·30 enrolled

Bladder Cancer1 trial

Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine

Unknown status·LLintonPharm Co.,Ltd.·Phase 1/2·NCT04799847·161 enrolled

Gastric Cancer1 trial

Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection

Completed·NNeovii Biotech·Phase 2·NCT00464893·70 enrolled

4 more indications

Gastric Carcinoma1 trial

Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis

Unknown status·LLintonPharm Co.,Ltd.·Phase 3·NCT04222114·282 enrolled

Gastric Adenocarcinoma1 trial

Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma

Completed·NNeovii Biotech·Phase 2·NCT00352833·40 enrolled

Intravenous1 trial

A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients

Terminated·NNeovii Biotech·Phase 1·NCT01320020·16 enrolled

Peritoneal Carcinomatosis1 trial

Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT01784900·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Catumaxomab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Catumaxomab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Catumaxomab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Neovii Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: NNeovii Biotech

Related News